Key result
Valsartan produced a greater reduction in left ventricular mass index than atenolol (mean reduction 21 vs 10 g/m2; Ratio 0.91, 90% CI 0.85-0.97) after 8 months of treatment.
Why the study?
Does valsartan reduce left ventricular mass index more than atenolol in patients with essential hypertension and left ventricular hypertrophy?
Population
69 predominantly previously untreated hypertensive patients with echocardiographically proven left…
Comparison
Valsartan for 8 months vs Atenolol for 8 months
Design
RCT, randomized, double-blind
Follow-up
8 months
Authors
Loading...
May support LVH regression with AT1 antagonists in hypertension; leaves open prognostic benefit in larger trials.
RCT (n=69)
Double-blind
randomized
Does valsartan reduce left ventricular mass index more than atenolol in patients with essential hypertension and left ventricular hypertrophy?
Effect estimate: Ratio 0.91 (95% CI 0.85-0.97 (90% CI))
Absolute Event Rate: 106% vs 117%
Valsartan produces a significantly greater regression of left ventricular hypertrophy compared to atenolol in patients with essential hypertension over an 8-month period.
Thürmann et al. (1998) conducted an RCT in Essential hypertension with left ventricular hypertrophy (n=69). Valsartan vs. Atenolol was evaluated on Left ventricular mass index (LVMI) (Ratio 0.91, 95% CI 0.85-0.97 (90% CI)). Valsartan produced a greater reduction in left ventricular mass index than atenolol (mean reduction 21 vs 10 g/m2; Ratio 0.91, 90% CI 0.85-0.97) after 8 months of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: